JANX Janux Therapeutics Inc: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik januxrx.com (JANX)

The price-to-sales ratio dynamics for Janux Therapeutics (JANX) correlate with expectations for the commercialization of TRACTr T-cell therapies. The potential for global dominance following molecule approval is currently superseded by a phase of costly clinical trials where expenses are growing linearly. The value of -12699.01 serves as a current metric that helps investors filter out market noise and assess the risk of overpaying for the asset.

Nilai perusahaan marang pendapatan: Janux Therapeutics Inc (JANX) kanggo 23.11.2025 - 20.11.2026

januxrx.com - rincian analitis lan metrik utama (JANX)

- rega saham lan konsensus proyeksi valuasi:
- informasi babagan dhuwit lan arus kas:
Analisis wiwitan perusahaan:Janux Therapeutics JANX
Sampel barang Janux Therapeutics

EV/Sales measures the total value of a business, including debt, relative to the volume of revenue generated. This multiple allows an investor to assess the efficiency of revenue capitalization regardless of the financing structure. By analyzing the EV/Sales value on the GURU.Markets platform, one can identify whether an asset is overvalued or undervalued. For Janux Therapeutics (JANX), the stability of this metric confirms market confidence in its operational resilience, which is further supported by robust diversification of biomedical component supplies for clinical trials.

Analisis pesaing Janux Therapeutics

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Arcus Bio (RCUS)|Nilai perusahaan marang pendapatan ZYME|TNGX - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan IOVA (Iovance)|Koefisien nilai perusahaan marang pendapatan IMTX|Multiplikator EV/Sales XNCR (Xencor)|Nilai bisnis marang pendapatan CMPX|replimune.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Lyell Pharma|Innate Pharma S.A. (IPHA) - Rasio nilai perusahaan marang pendapatan|Pyxis Oncology Inc. - Nilai bisnis marang pendapatan|CGEN (Compugen Limited) - Multiplikator EV/Sales|Multiplikator EV/Sales IO Biotech Inc|Rasio nilai perusahaan marang pendapatan Sutro Biopharma (STRO)|INKT: Nilai perusahaan marang volume dodolan|Werewolf Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Immix (IMMX) - Multiplikator nilai perusahaan marang pendapatan|ALX Oncology Holdings Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP